Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12936
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Katherine J | en |
dc.contributor.author | Horowitz, J D | en |
dc.contributor.author | McKay, W J | en |
dc.contributor.author | Goble, A J | en |
dc.date.accessioned | 2015-05-16T02:41:59Z | |
dc.date.available | 2015-05-16T02:41:59Z | |
dc.date.issued | 1988-12-01 | en |
dc.identifier.citation | International Journal of Cardiology; 21(3): 279-91 | en |
dc.identifier.govdoc | 3147949 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12936 | en |
dc.description.abstract | We tested the hypothesis that preservation of left ventricular function results from treatment with intravenous streptokinase given in the first 2 hours from onset of acute transmural myocardial infarction together with nitroglycerine and verapamil. Thirty-three consecutive patients with onset of pain less than 2 hours prior to admission, received intravenous streptokinase 1.5 x 10(6) units with intravenous nitroglycerine and verapamil; 23 concurrently admitted "control" patients with pain onset 2-4 hours received intravenous nitroglycerine and verapamil only. Radionuclide ventriculographic assessment at 2 days revealed a significantly greater left ventricular ejection fraction in the streptokinase-treated patients (54.5 +/- 2.8 vs 46.1 +/- 2.9; P less than 0.05), which persisted at 28-35 days (50.1 +/- 2.3 vs 41.2 +/- 2.9; P less than 0.05). Streptokinase-treated patients had a significantly increased incidence of ischaemic events in the 35 days following infarction, but a lower incidence of death, congestive cardiac failure and non-fatal ventricular tachycardia than control group patients. Infarct-related artery patency assessed at 3-5 days was 94% in streptokinase-treated patients. We conclude that early presentation and treatment with intravenous streptokinase, nitroglycerine and verapamil is associated with a high incidence of successful thrombolysis and significant preservation of left ventricular function. Nitroglycerine and verapamil may augment the efficacy of streptokinase in this group of patients. | en |
dc.language.iso | en | en |
dc.subject.other | Acute Disease | en |
dc.subject.other | Drug Therapy, Combination | en |
dc.subject.other | Female | en |
dc.subject.other | Heart Ventricles.radionuclide imaging | en |
dc.subject.other | Humans | en |
dc.subject.other | Male | en |
dc.subject.other | Middle Aged | en |
dc.subject.other | Myocardial Infarction.drug therapy.mortality | en |
dc.subject.other | Myocardial Reperfusion | en |
dc.subject.other | Nitroglycerin.therapeutic use | en |
dc.subject.other | Streptokinase.therapeutic use | en |
dc.subject.other | Stroke Volume.drug effects | en |
dc.subject.other | Verapamil.therapeutic use | en |
dc.title | Myocardial salvage with streptokinase combined with nitroglycerine and verapamil in acute myocardial infarction. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | International journal of cardiology | en |
dc.identifier.affiliation | Austin Hospital, Heidelberg, Victoria, Australia | en |
dc.description.pages | 279-91 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/3147949 | en |
dc.type.austin | Journal Article | en |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.